SCHEMBL12701205

SCHEMBL12701205

COC(=O)c1cc(Cl)nc(Cl)c1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.54
SMN1; SMN2 Q16637 3/20 0.43
ALDH1A1 P00352 3/20 0.43
NPC1 O15118 1/20 0.42
MAPT P10636 1/20 0.42
NFKB1 P19838 1/20 0.42
RAB9A P51151 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ABL1 P00519 1/20 0.41
NQO2 P16083 4/20 0.39
RXFP1 Q9HBX9 1/20 0.39
GAA P10253 2/20 0.39
HPGD P15428 1/20 0.39
TUBB4A P04350 1/20 0.38
TUBB P07437 1/20 0.38
TUBA3C P0DPH7 1/20 0.38
TUBA1B P68363 1/20 0.38
TUBA4A P68366 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29592465 1.00 KDM4E (0.54) KDM4ESMN1; SMN2ALDH1A1NPC1MAPT
SCHEMBL31267853 0.83 L3MBTL1 (0.41) KDM4ESMN1; SMN2ALDH1A1NPC1MAPT
SCHEMBL16761769 0.83 KDM4E (0.49) KDM4ESMN1; SMN2ALDH1A1NPC1MAPT
SCHEMBL1579279 0.83 ALDH1A1 (0.47) KDM4ESMN1; SMN2ALDH1A1NPC1MAPT
SCHEMBL30416311 0.83 ALDH1A1 (0.47) KDM4ESMN1; SMN2ALDH1A1NPC1MAPT
SCHEMBL25343847 0.82 KDM4E (0.54) KDM4ESMN1; SMN2ALDH1A1NPC1MAPT
SCHEMBL8606526 0.82 KDM4E (0.54) KDM4ESMN1; SMN2ALDH1A1NPC1MAPT
SCHEMBL31729407 0.81 KDM4E (0.56) KDM4ESMN1; SMN2ALDH1A1NPC1MAPT
SCHEMBL21349700 0.81 KDM4E (0.53) KDM4ESMN1; SMN2ALDH1A1NPC1MAPT
SCHEMBL31729133 0.81 KDM4E (0.56) KDM4ESMN1; SMN2ALDH1A1NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3484882-B1 ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR ZHEJIANG METON PHARMACEUTICAL CO LTD (CN) 2022-04-27 EP disclosed
CN-109641890-B Isocitrate Dehydrogenase (IDH) inhibitors 浙江迈同生物医药有限公司 2022-04-26 CN disclosed
US-10752626-B2 Iso-citrate dehydrogenase (IDH) inhibitor SHANGHAI METON PHARMACEUTICAL CO., LTD (CN) 2020-08-25 US disclosed
US-20190256511-A1 ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR ZHEJIANG METON PHARMACEUTICAL CO., LTD (CN) 2019-08-22 US disclosed
US-20110092505-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-04-21 US disclosed
US-20110092505-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190256511-A1 ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR IDH3A, IDH2, IDH1 KDM4E 626/4885SMN1; SMN2 3374/4885ALDH1A1 499/4885
US-10752626-B2 Iso-citrate dehydrogenase (IDH) inhibitor IDH3A, IDH2, IDH1 KDM4E 626/4885SMN1; SMN2 3374/4885ALDH1A1 499/4885
US-20110092505-A1 ORGANIC COMPOUNDS SLCO2B1, SLCO1B1, SLCO1B3 KDM4E 3921/4885SMN1; SMN2 3700/4885ALDH1A1 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.